GENETICALY DETERMINED ELEVATION OF THROMBOGENIC POTENTIAL OF BLOOD IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS
https://doi.org/10.24884/1561-6274-2008-12-2-52-55
Abstract
THE AIM of the investigation was to study the occurrence and clinic-pathogenetic value of prothrombotic genotypes which are of the greatest clinical and prognosic value among hematogenic thrombophilias. PATIENTS AND METHODS. Examination was performed in 180 patients with chronic glomerulonephritis (mean age 22.3±0.8 years). In addition to complete clinical and instrumental examination used at the specialized nephrological clinic, with the help of polymerase chain reaction the diagnosis of a single nucleotide change of C677T in the gene of methylenetetrahydrofolate reductase, punctated gene mutation of V factor of blood coagulation, and G20210A mutation in 3’ nontranslated area of gene of II factor of blood coagulation (samples of genomic DNA was obtained from peripheral blood leukocytes by the method of phenol-chloroform extraction). The control group included 100 healthy subjects with similar demographic characteristics. RESULTS. It was found thst protrombogenic mutations under study can be found in patients with chronic glomerulonephritis more often than among healthy subjects. These nucleotide changes are associated with the development of hypercoagulation syndrome and high risk of renal failure in patients with chronic glomerulonephritis. CONCLUSION. The results of thisinvestigation show that at least part of the patients with chronic glomerulonephritis have genetically determined elevation of thrombogenic potential of blood.
About the Authors
O. F. Simbirtseva
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
E. Yu. Khitrinskaya
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
I. I. Ivanchuk
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
V. V. Kalyuzhin
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
L. I. Zibnitskaya
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
L. M. Tkalich
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
E. V. Kalyuzhina
Сибирский государственный медицинский университет, г. Томск
Russian Federation
Russian Federation
References
1. Тареева ИЕ, Мухин НА. Механизмы прогрессирования нефрита. В: Тареева ИЕ, ред. Нефрология: руководство для врачей. Том. 2. Медицина, М., 2000; 20-28
2. Рябов СИ. Нефрология: руководство для врачей. СпецЛит, СПб., 2000; 672
3. Шулутко БИ. Нефрология 2002. Современное состояние проблемы. Ренкор, СПб., 2002; 780
4. Глессок РД, Бреннер БМ. Иммунопатогенетические механизмы повреждения почек. В: Браунвальд Е, Иссельбахер КДж, Петерсдорф РГ, ред. Внутренние болезни.Книга. 6. Медицина, М., 1995; 282-289
5. Спиридонова МГ, Степанов ВА, Пузырев ВП. О роли полиморфных вариантов гена 5,10–метилентетрагидрофо-латредуктазы (MTHFR) в патогенезе сердечно-сосудистых заболеваний. Клин мед 2001; (2): 10-16
6. Rosenberg N, Murata M, Ikeda Y et al. The Frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, japanese, and africans. Am J Hum Genet 2002; 71: 758-762
7. Добронравов ВА, Голубев РВ. Гипергомоцистеинемия – фактор риска сердечно-сосудистых поражений у диализных больных и в общей популяции. Нефрология 2004; (2): 44-49
8. Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 С to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523
9. Момот АП. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. Форма Т, СПб., 2006; 208
10. Насонов ЕЛ. Антифосфолипидный синдром. Литтерра, М., 2004; 440
11. Irish A. The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. Nephrol Dial Transplant 1997; 12: 1680-1683
12. Aucella F, Margaglione M, Grandone E et al. On behalf of The Genetic Polymorphisms in Dialysis Study Group. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant 2004; 20 (2): 382-386
13. Haviv YS, Shpichinetsky V, Goldschmidt N et al. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126
14. Morimoto K, Haneda T, Okamoto K et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron 2002; 90: 43-50
15. Quintana LF, Cofan F, Reverte JC et al. Renal cortical necrosis after kidney transplantation associated with the prothrombin 20210A mutation. Nephrol Dial Transplant 2006; 21 (5): 1455-1456
16. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004; 4: 139-149
17. Heidenreich S, Junker R, Wolters H et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14: 234-239
18. Heidenreich S, Junker R, Wolters H. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003; 14 (1): 234-239
19. Zychma MJ, Gumprecht J, Grzeszczak W, Zukowska-Szczechowska E. Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients. Nephron 2002; 92: 235-239
20. Winkelmayer WC, Kramar R, Sunder-Plassmann G, Fцdinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. Kidney Int 2005; 68: 2857-2862
21. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957
22. Kabukcu S. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of denizli. Clinical and Applied Thrombosis / Hemostasis 2007; 13 (2): 166-171
Review
For citations:
Simbirtseva O.F., Khitrinskaya E.Yu., Ivanchuk I.I., Kalyuzhin V.V., Zibnitskaya L.I., Tkalich L.M., Kalyuzhina E.V. GENETICALY DETERMINED ELEVATION OF THROMBOGENIC POTENTIAL OF BLOOD IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS. Nephrology (Saint-Petersburg). 2008;12(2):52-55. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-2-52-55
Views:
343
Email this article 